Burt Adelman, M.D.
Veteran drug-development leader and biotech board director
Summary
Experienced biotech drug-development leader who has guided multiple late-stage programs from discovery through approval pathways, with a particular track record in biologics and monoclonal antibodies. iecure+2
Senior executive and operational leader with long tenures in major biotech companies, including multiple EVP roles at Biogen and C-suite leadership at Dyax, responsible for clinical, regulatory and portfolio strategy functions. idecpharm+2
Active board member, chairman and advisor across startups and public companies, participating in governance and strategic guidance for companies spanning gene editing, oncology, and rare-disease therapeutics. biospace+2
Clinician-scientist background with academic appointments and published clinical research and patents, combining medical training (M.D.) and hematology fellowship with translational research output. rivatherapeutics+2
Work
Education
Projects
Writing
Inhibiting Plasma Kallikrein for Hereditary Angioedema
January 1, 2017Peer-reviewed article describing inhibition of plasma kallikrein (lanadelumab) as a therapeutic approach for hereditary angioedema.
A phase 1 study investigating DX-2930 in healthy subjects
January 1, 2014Phase I randomized, double-blind study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of DX-2930 in healthy volunteers.
Patent portfolio on plasma kallikrein inhibitors and related assays
Multiple patent filings and granted patents related to plasma kallikrein binding proteins, assays for kallikrein system biomarkers, monoclonal inhibitors of Factor XIIa, and bispecific antibodies relevant to hereditary angioedema and related disorders.